vaccine

(redirected from dendritic cell vaccine)
Also found in: Dictionary, Medical, Encyclopedia.
Related to dendritic cell vaccine: sipuleucel-T
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for vaccine

Synonyms for vaccine

immunogen consisting of a suspension of weakened or dead pathogenic cells injected in order to stimulate the production of antibodies

References in periodicals archive ?
Dendritic cell vaccines provide another form of therapy for conditions that cannot be addressed with chemotherapy or radiation, such as metastatic renal cancer or malignant melanoma.
Under the new agreement, PCT will manufacture clinical supplies of ICT-140, a dendritic cell vaccine targeting seven ovarian cancer antigens, using process improvements PCT will develop that can be applied to the manufacture of all ImmunoCellular's current vaccine product candidates, ICT-107, ICT-121 and ICT-140.
The vaccine, called sipuleucel-t (Provenge), is a dendritic cell vaccine that treats advanced prostate cancer that no longer responds to hormone therapy.
Nierkens et al., "Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine," Cancer Research, vol.
Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
Eight patients in the dendritic cell vaccine study experienced remarkable long-term, progression-free survival after completing the vaccine therapy, even though they had widely metastatic disease and/or repeated appearance of new metastases despite various therapies.
The ovarian Phase II double-blind study will enroll approximately 99 patients who will be randomized in a 2:1 ratio to receive either autologous dendritic cell vaccine or autologous monocytes as a comparator.
For example, the dendritic cell vaccine, provenge (sipuleucel-T), targeting PAP for metastatic castration-resistant prostate cancer, was the first FDA-approved cell-based cancer vaccine in 2010 [59].
According to the new Services Agreement, Progenitor Cell Therapy will produce clinical supplies of ICT-140, a dendritic cell vaccine targeting seven ovarian cancer antigens, using process improvements.
ICT-140 is a dendritic cell vaccine targeting seven antigens that are over-expressed in ovarian cancer, as well as cancer stem cells.
A dendritic cell vaccine personalized for each individual based on the patient's own tumor may increase median survival time in those with a deadly form of brain cancer called glioblastoma, an early-phase study at UCLA's Jonsson Comprehensive Cancer Center has found.